<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Taliglucerase Alfa</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08876</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, &#946;-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher&#8217;s disease.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>2580</sub>H<sub>3918</sub>N<sub>680</sub>O<sub>727</sub>S<sub>17</sub></td></tr><tr><th>Protein average weight</th><td>56637.9397 g/mol</td></tr><tr><th>Sequences</th><td></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>prGCD</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Elelyso</td><td>PFIZER</td></tr><tr><td>UPLYSO</td><td>PFIZER</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/enzymes">Enzymes</a></li></ul></td></tr><tr><th>CAS number</th><td>37228-64-1</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of adult Type 1 Gaucher disease. </td></tr><tr><th>Pharmacodynamics</th><td>Patient's with Type 1 Gaucher disease have a long-term deficiency in the enzyme, glucocerebrosidase. Taliglucerase alfa is a modified form of glucocerebrosidase and is provided to counter this enzyme deficiency, resulting in smaller liver and spleen size, and improved thrombocytopenia and anemia.</td></tr><tr><th>Mechanism of action</th><td>Taliglucerase alfa is different from human glucocerebrosidase by two amino acids at the N terminal and up to 7 amino acids at the C terminal. This recombinant enzyme allows the hydrolysis reaction of glucocerebroside to glucose and ceramide that naturally occurs in healthy individuals.</td></tr><tr><th>Absorption</th><td>Taliglucerase alfa is administered IV so absorption is 100%.</td></tr><tr><th>Volume of distribution</th><td><p>The steady state volume of distribution is between 7.30 to 11.7 L.</p></td></tr><tr><th>Protein binding</th><td>Plasma protein binding was not quantified.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolism was not determined.</p></td></tr><tr><th>Route of elimination</th><td>Route of elimination was not determined.</td></tr><tr><th>Half life</th><td>The half life is between 18.9 to 28.7 min.</td></tr><tr><th>Clearance</th><td><p>The systemic clearance was approximately 30 L/hr and 20 L/hr for 30 and 60 units/kg, respectively.</p></td></tr><tr><th>Toxicity</th><td>The most common toxic reaction seen was infusion reactions such as urticaria, arthralgia, headache, and chest pain due to IV administration.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, for solution</td><td>Intravenous</td><td>200 UNITS/VIAL</td></tr></tbody></table></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td>Searched, but no interactions found.</td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>